Andrew Branagan is an Oncology physician affiliated with Harvard University. OpenAlex indexes 211 publications with 5,631 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142621
Telephone
617-726-2000Registry record last updated 17 Mar 2018.
Clinical trials
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Sponsor: Massachusetts General Hospital
- Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Sponsor: Massachusetts General Hospital
- Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20254 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- BeiGene, Ltd.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.8%Kinase inhibitor86.8%Brukinsa80%Imbruvica11%Calquence10%Part D<11 patientsNervous system
13.2%Other antidepressants13.2%Mirtazapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”